Azitra, Inc. (AZTR) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-22

Key Insights

Travis Whitfill, Chief Operating Officer and Director, received a stock option grant of 64,300 shares at an exercise price of $0.2127, granted on 04/20/2026 with a 10-year expiration, indicating the company is using equity compensation for executive retention.
The option vests over 3 years with 1/3 vesting at one year and then 1/36 monthly thereafter, a standard vesting schedule that aligns executive incentives with long-term company performance and reduces immediate dilution concerns.
This is an option grant rather than a direct stock purchase, suggesting no immediate insider confidence signal about the stock's current valuation, though it does represent a meaningful equity stake for the COO.

Want the newest filings?

This analysis covers the filing from 2026-04-22. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-22

Francisco D. Salva, President and CEO, received a grant of 220,879 stock options on 04/20/2026 with an exercise price of $0.2127, indicating the company's current valuation near this price point.
The options follow a standard 3-year vesting schedule (1/3 after one year, then monthly over 24 months), which is typical for executive compensation and aligns management incentives with long-term company performance.
As the CEO and a 10% owner, Salva's option grant represents continued equity participation in the company, though this is a standard compensation arrangement rather than discretionary insider buying, which could suggest confidence in future prospects.
No sale or disposition of existing securities is reported, indicating the CEO is not reducing his position in the company during this filing period.

Filed: 2026-04-22

CFO Norman Staskey received a stock option grant of 35,524 shares at an exercise price of $0.2127, suggesting the company is using equity compensation to retain executive talent.
The option has a 10-year expiration (04/20/2036) with a 3-year vesting schedule (1/3 at one year, then monthly vesting), indicating a medium-term incentive alignment with company performance.
The relatively modest option grant size and low exercise price may reflect either early-stage valuation challenges or modest compensation positioning for the CFO role at this small-cap biotech company.
This is a routine equity grant transaction with no indication of insider selling pressure or confidence signals from significant stock purchases by the reporting person.

Filed: 2026-03-20

The reporting person, Francisco D. Salva, is the President and CEO of Azitra, Inc., indicating high-level insider involvement.
Salva acquired 500 shares of Series A Convertible Non-Redeemable Preferred Stock, as well as 4,064,050 Series B and Series C Warrants, suggesting potential future investment in the company.
The conversion of the Series A Preferred Stock and exercise of the Series B and C Warrants are subject to shareholder approval, which could be a key milestone for the company.

Other reports for Azitra, Inc.

Current Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.